Operator
Good day, and thank you for standing by, and welcome to the Silk Road Medical s 2021 Second Quarter Earnings. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Caroline Paul, Investor Relations. Please go ahead.
Caroline Paul
Investor Relations
Thank you, and thank you all for participating in today s call. Joining me are Erica Rogers, Chief Executive Officer and Lucas Buchanan, Chief Financial Officer and Chief Operating Officer. Earlier today, Silk Road Medical released financial results for the three months ended June 30, 2021. A copy of the press release is available on the company s website. Before we begin, I d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Dedicated rare disease unit to be headquartered in Boston
Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care
Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio
Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend
The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities
December 12, 2020 07:48 AM Eastern Standard Time – CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
12 december 2020 kl 13:59
Greater scientific presence in immunology by adding Alexion s innovative complement-technology platforms and strong pipeline
Dedicated rare disease unit to be headquartered in Boston
Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care
Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca s broad-based revenue and the company will further globalise Alexion s portfolio
Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend
The acquisition will be immediately core earnings-accretive andvalue-enhancing, and is aligned with stated capital-allocation priorities
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development
December 12, 2020 GMT
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Dec 12, 2020
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.